Mescaline: Effects, Cactus Sources, and Pharmacology

Mescaline is a naturally occurring psychedelic compound found in several species of cactus, most famously peyote and San Pedro. Chemically, it belongs to the phenethylamine family, which makes it structurally distinct from other well-known psychedelics like psilocybin and LSD, both of which are tryptamines. Despite being one of the first psychedelics studied by Western science and used ceremonially by Indigenous peoples for thousands of years, mescaline has received far less modern clinical attention than its better-known cousins. That gap has begun to close, with recent research mapping out everything from how the cactus builds the molecule to how the human body processes and eliminates it.

Where Mescaline Comes From

Peyote (Lophophora williamsii), a small, spineless cactus native to the Chihuahuan Desert and parts of southern Texas, is the plant most associated with mescaline. But it is not the only source. San Pedro (Trichocereus species), a tall columnar cactus widely cultivated in South America and elsewhere, also produces mescaline at pharmacologically meaningful concentrations. A handful of other cacti contain it too, though generally in smaller amounts.

Within a San Pedro cactus, mescaline is not evenly distributed. The green outer flesh, called chlorenchyma, tends to have higher concentrations than the white inner tissue, or parenchyma. But the inner tissue makes up the vast majority of the cactus by weight, so it actually contributes substantially to the total mescaline content. In one analysis of San Pedro cultivars, the ratio of mescaline concentration between the outer and inner tissue ranged from roughly 4-to-1 down to about 2-to-1 depending on the cultivar, and accounting for the inner tissue’s larger mass more than doubled the estimated total yield for some varieties.¹ This matters for anyone estimating what a given piece of cactus contains, and it upends the old assumption that only the green rind is worth attention.

How the Cactus Builds the Molecule

Mescaline’s biosynthetic pathway was a longstanding puzzle. Researchers knew the starting material was the amino acid tyrosine, a common building block in plants and animals, but the specific enzymes catalyzing each step remained elusive until very recently. Two research groups working independently pieced the pathway together in 2023 and 2024. One team used gene-discovery techniques in peyote and identified a cytochrome P450 enzyme that converts tyrosine to L-DOPA, followed by a decarboxylase that produces dopamine, and then four specialized methyltransferase enzymes that add methyl groups in a specific sequence to arrive at mescaline.² A second group confirmed the overall architecture, identifying four groups of enzymes responsible for six catalytic steps, and additionally found an enzyme that adds a methyl group to nitrogen on the intermediate molecules, which likely helps the plant regulate how much mescaline it accumulates.³

The practical significance of mapping this pathway goes beyond academic curiosity. With the genes identified, scientists can in principle reconstruct mescaline production in other organisms, such as yeast or tobacco, using synthetic biology. That opens the door to sustainable laboratory production without harvesting wild or cultivated cacti, a prospect with real conservation implications for peyote.

What Happens After You Take It

Mescaline’s pharmacokinetics have now been characterized in a placebo-controlled clinical study, something that had never been done with modern analytical tools until recently. After an oral dose of mescaline hydrochloride, blood levels peak at about two hours and the elimination half-life is roughly three and a half hours.⁴ That half-life might seem short for a substance whose subjective effects can last ten hours or more, but the explanation lies in slow absorption: the drug enters the bloodstream gradually enough that effects persist well beyond what the half-life alone would predict.

The body eliminates mescaline primarily through the kidneys. About half of an oral dose is excreted unchanged in urine, and roughly a third is converted to a metabolite called 3,4,5-trimethoxyphenylacetic acid before being excreted. Together, those two routes account for the majority of a dose within 24 to 30 hours. Based on the urinary recovery data, oral bioavailability is at least 53%, with the remainder lost to first-pass metabolism in the liver.⁵ Exposure scales proportionally with dose, meaning that doubling the dose roughly doubles the peak blood concentration and total exposure, at least in principle. In practice, higher doses cause more nausea and vomiting, which can reduce how much is actually absorbed.

Physical Effects and Safety

Like other serotonergic psychedelics, mescaline produces measurable changes in heart rate, blood pressure, body temperature, and pupil size. A dose-ranging safety study in healthy volunteers found that these autonomic effects were generally moderate. Systolic blood pressure stayed below 180 mmHg in all participants across all doses tested (100 to 800 mg). Diastolic blood pressure exceeded 100 mmHg in about 6% of administrations, heart rate went above 100 beats per minute in about 3%, and body temperature exceeded 38°C in about 5%.⁶ Those numbers suggest that mescaline’s cardiovascular burden, while real, stays within a range most healthy adults can handle.

Nausea is the dose-limiting side effect. The total number of reported adverse effects climbed steeply with dose, and vomiting at higher doses was common enough that it actually interfered with drug absorption in the pharmacokinetic analyses. When the highest dose (800 mg) was co-administered with ketanserin, a serotonin receptor blocker, vomiting decreased and blood concentrations reached the expected range.⁷ Ketanserin also significantly reduced the peak effect of mescaline on heart rate and body temperature, confirming that many of mescaline’s physiological effects run through the serotonin 5-HT2A receptor system. Blood pressure elevations were less clearly reversed by ketanserin, possibly because they occurred faster than the blocker could take effect.

People with uncontrolled hypertension or serious cardiovascular conditions face obvious risks from any substance that raises blood pressure and heart rate, even transiently. The clinical studies screened out such individuals, so the safety data should be interpreted as applying to healthy adults in a controlled setting.

The Psychedelic Experience

Mescaline produces visual, emotional, and cognitive effects broadly similar to other classical psychedelics, though users and researchers both describe its character as having its own flavor. Visual effects include vivid color enhancement, geometric patterns, and altered perception of shapes and space. A long tradition of research, stretching back to the early twentieth century, cataloged the geometric hallucinations produced by mescaline and other psychedelics into recurring forms: tunnels and funnels, spirals, lattice-like honeycombs and triangles, and cobweb patterns. These so-called form constants appear across different psychedelics and even in non-drug contexts like flickering lights and near-death experiences, and computational modeling has linked them to the way activity patterns in the primary visual cortex map onto the visual field.⁸ In other words, the geometry you see on mescaline reflects the architecture of your own brain as much as it does the drug itself.

Emotionally, mescaline can produce feelings ranging from profound awe and connectedness to anxiety and confusion, depending heavily on dose, mindset, and setting. Higher doses are more likely to produce ego dissolution, a loosening of the ordinary sense of self, which can be experienced as either transcendent or destabilizing. The subjective effects of mescaline tend to last longer than those of psilocybin, often in the range of eight to twelve hours, a consequence of its slow absorption rather than a long half-life.

Cultural Use and Legal Status

Peyote has been used in spiritual and healing ceremonies by Indigenous peoples of Mexico and the American Southwest for at least several thousand years. In the United States, the Native American Church has legal protection for sacramental peyote use, and some American Indian youth participate in both spiritual and, to a lesser degree, recreational peyote use.⁹ Outside this religious exemption, mescaline is classified as a Schedule I controlled substance in the United States, and peyote and San Pedro are similarly restricted in many other countries, though enforcement varies considerably. Some jurisdictions treat growing San Pedro as an ornamental cactus as legal while criminalizing extraction or consumption.

The legal patchwork creates a strange situation. Peyote is simultaneously a protected sacrament, a federally scheduled drug, and an endangered plant. Those three identities pull in different directions, and the tension shows up in conservation debates, access questions for Indigenous communities, and the broader psychedelic decriminalization movement.

Peyote Conservation

Wild peyote is under real pressure. The cactus grows extremely slowly, sometimes taking a decade or more to reach maturity, and its natural habitat in southern Texas and northern Mexico has been shrinking due to land-use changes, brush clearing, and harvesting. A comparative survey of peyote populations in two Texas regions found that plants in western Texas were significantly larger on average than those in southern Texas, and that population densities were slightly higher in the west, driven largely by one site with no known harvesting history.¹⁰ In both regions, most plants had only one or two crowns, suggesting relatively young or slow-growing populations.

Harvesting practices matter enormously. When peyote is harvested correctly by cutting above the root, the plant can regrow, though slowly. When the root is damaged or the whole plant pulled out, recovery is unlikely. The combination of slow growth, habitat loss, and demand from both ceremonial and non-ceremonial users creates a sustainability problem that has no easy fix. Proposals range from establishing peyote gardens and cultivation programs to developing biosynthetic production methods that remove wild harvesting from the equation entirely.

Therapeutic Research

Mescaline has historically been sidelined in the psychedelic therapy renaissance, with psilocybin and MDMA absorbing most clinical investment. But early signals from observational research suggest therapeutic potential worth exploring. A large survey study found that among people who reported histories of depression, anxiety, PTSD, or substance use disorders, between 68% and 86% reported subjective improvement following a memorable mescaline experience. Those who reported improvement also scored significantly higher on measures of mystical-type experiences, psychological insight, and ego dissolution during the session.¹¹ Experiences of psychological insight were specifically associated with greater odds of reporting improvement in depression, anxiety, and substance use problems.

These are self-reported, retrospective data from people who chose to use mescaline, so they cannot establish that mescaline caused the improvements. Selection bias, expectation effects, and memory distortion all limit what you can conclude. Still, the pattern is consistent with what controlled trials have shown for psilocybin, and mescaline’s longer duration of action and distinct pharmacological profile make it a plausible candidate for formal clinical trials. A review paper described mescaline as “the forgotten psychedelic” and argued that its reported ability to improve mental well-being and help with alcoholism warrants clinical investigation.¹²

How Tweaking the Molecule Changes Its Effects

Mescaline’s structure is simple enough that chemists have been modifying it for decades to understand which parts of the molecule matter for psychedelic activity. The three methoxy groups on the ring are central. Removing the methoxy group at the 5-position (the one farthest from the amine side chain) decreases potency, while replacing the 3,4-dimethoxy groups with a methylenedioxy bridge (the substitution that produces the related compound MMDA) increases it.¹³ Adding a methyl group to the alpha carbon of the side chain, the modification that turns mescaline into the more potent compound TMA, also ramps up activity.

At the 4-position (para to the side chain), swapping in a sulfur atom or lengthening the alkyl chain to three carbons retains or even boosts potency, but extending it to four carbons causes activity to drop off.¹⁴ The pattern emerging from decades of this kind of work is that small, targeted modifications to mescaline’s ring or side chain can create compounds many times more potent per milligram, or can eliminate psychedelic activity altogether. This is part of why mescaline itself requires a relatively large dose (hundreds of milligrams) to produce effects, while related phenethylamines like 2C-B work at a fraction of that weight. Mescaline’s three methoxy groups make it a somewhat weak agonist at the receptors that drive psychedelic effects; small structural changes can tighten that binding dramatically.

Detecting Mescaline in the Body

Standard drug screening panels do not test for mescaline. Detecting it requires targeted analytical methods, and several have been developed for forensic and clinical use. For urine testing, liquid chromatography coupled with tandem mass spectrometry can detect mescaline at concentrations as low as 3 to 5 micrograms per liter, with a quantification range up to 10,000 micrograms per liter.¹⁵ Given that over half the dose is excreted unchanged in urine, the detection window is relatively generous compared to some other substances, though it still closes within a few days.

For blood, a validated method can simultaneously measure mescaline and its major metabolites, including the primary oxidative metabolite (3,4,5-trimethoxyphenylacetic acid), an acetylated form, and a demethylated form.¹⁶ Hair testing offers the longest detection window. A method validated against 19 real forensic cases can detect mescaline in hair at concentrations as low as 3 picograms per milligram, with results available in a five-minute analytical run.¹⁷ Hair testing can potentially reveal use going back months, depending on hair length and growth rate.

Tolerance and Cross-Tolerance

Like other psychedelics that work through the serotonin 5-HT2A receptor, mescaline produces rapid tolerance. Taking the same dose on consecutive days yields progressively weaker effects. The mechanism appears to involve downregulation of the receptor itself: after exposure to a 5-HT2A agonist, the number of available receptors on the cell surface drops measurably within 24 hours. Research in animal models has shown that this tolerance crosses over between different psychedelics. Repeated dosing with LSD, for example, blunts the response to DOI (another 5-HT2A agonist), and vice versa.¹⁸ This cross-tolerance is generally understood to extend to mescaline and psilocybin as well, since all three work through the same receptor.

The practical upshot is that spacing sessions at least a week or two apart is necessary to experience full effects. This built-in tolerance also makes compulsive daily use essentially self-defeating, which is one reason classical psychedelics including mescaline are generally considered to have low addiction potential. You cannot chase the high by taking more the next day, because the receptors have temporarily retreated.